Scholars Central

Conference abstractPublished 4 Oct 2022

Application of the next generation L-PDT with talaporfin sodium (Laserphyrin) for Cervical Intraepithelial Neoplasia (CIN)

Authors: Masaru Sakamoto

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We have treated more than 900 cases of CIN and uterine cervical cancer using PDT with Photofrin (P-PDT) (Sakamoto, et al. In: Cryosurgery and Colposcopy, Nova Science Publishers, p127-144, 2016). PDT is considered to be a treatment modality with higher fertility sparing capacity than cone resection as uterine preservation therapy for CIN3. P-PDT has high efficacy for CIN and has low obstetric risks such as premature delivery after P-PDT. However, the side effect of photosensitivity is strong and the hospitalization period is long, so P-PDT has not reached standard treatment. In order to investigate the safety and effectiveness of L-PDT using semiconductor laser and Laserphyrin with less half-life in blood, we started Phase I/II study of L-PDT after registration to UMIN. Methods: After approval of the ethical committee, phase I/II study of L-PDT was performed on 43 cases of CIN2-3 with IC. Phase I study was performed to investigate safety and the optimal dose of laser irradiation. Three cases were performed for each step of 50, 75 and 100 J/cm2. Phase II study was performed to further investigate safety and effectiveness of L-PDT with recommended dose of 100 J/cm2. [Results]Intra-tumor accumulation of Laserphyrin was confirmed by Fluorescence microscopy. Dose Limiting Toxicity was not observed. The main side effects were lower abdominal pain of G1-2 and fever of G1-2. Photosensitivity of G1 within 15 days was seen only in 3/43 cases (7%). Histological disappearance of CIN2-3 was observed in 41/43, 42/43 cases at 3, 6 months after L-PDT, respectively. Conclusion: Although temporary lower abdominal pain and fever were observed in L-PDT, photosensitivity was hardly seen unlike P-PDT, suggesting safety. CR rates 3 and 6 months after L-PDT were 95 and 98%, suggesting efficacy. These data suggested L-PDT would become the next generation PDT for CIN as uterine preservation therapy. Recent Publications: 1. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002 Sep 1;62(17):4860-6. PMID: 12208731. 2. Sakamoto M. Safety guidelines for photodynamic therapy in the treatment of early stage cancer and dysplasia of the uterine cervix. Laser Ther. 2012 Mar 28;21(1):60-4. doi: 10.5978/islsm.12-SG-02. PMID: 24610984; PMCID: PMC3944600. 3. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women Sakamoto, Masaru et al. Journal of Infection and Chemotherapy, Volume 25, Issue 7, 520 – 525 4. Harano N, Sakamoto M, Fukushima S, Iwai S, Koike Y, Horikawa S, Suzuki K, Narui C, Matsuoka K, Ozeki R, Iwaya K, Umayahara K, Tanaka T, Okamoto A. Clinical Study of Sentinel Lymph Node Detection Using Photodynamic Eye for Abdominal Radical Trachelectomy. Current Oncology. 2021; 28(6):4709-4720. https://doi.org/10.3390/curroncol28060397.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nursing Research and Practice
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Masaru Sakamoto”